Synta Announces Publication of Results Showing Ganetespib Exhibits Potent Activity in Models of Cancer with Activated JAK/STAT Signaling

Synta Pharmaceuticals Corp. SNTA today announced the publication in the on-line edition of the journal PLoS ONE of results demonstrating that ganetespib, a potent second generation inhibitor of heat shock protein 90, exhibits potent in vitro and in vivo activity in a range of solid and hematologic tumor cells that are dependent on Janus-associated kinase 2 activity for growth and survival.